Published in J Clin Oncol on January 01, 1997
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol (2010) 3.19
Systemic treatment of colorectal cancer. Gastroenterology (2008) 2.62
Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer (2001) 2.12
Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut (2002) 1.81
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
Colon cancer in France: evidence for improvement in management and survival. Gut (2002) 1.34
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer (2006) 1.22
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer (2009) 1.13
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer (2009) 1.10
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer (2003) 1.10
Challenges in the management of stage II colon cancer. Semin Oncol (2011) 1.09
Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer (1998) 1.06
Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients. Br J Cancer (2007) 1.05
Metastatic colorectal cancer-past, progress and future. World J Gastroenterol (2007) 1.04
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer (2006) 1.00
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol (2011) 0.98
The Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colorectal Cancer is Independent of Age and Comorbidity. J Geriatr Oncol (2010) 0.97
Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. Int J Colorectal Dis (2005) 0.97
Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res (2007) 0.95
Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol (2002) 0.95
Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. Sci Rep (2015) 0.95
Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. Gastrointest Cancer Res (2009) 0.91
Adherence to clinical practice guidelines for adjuvant chemotherapy for colorectal cancer in a Canadian province: a population-based analysis. J Oncol Pract (2012) 0.91
Adjuvant colon cancer chemotherapy: Is there an Indian standard of care? South Asian J Cancer (2013) 0.90
The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. Trials (2011) 0.89
An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. Br J Cancer (2007) 0.89
Time dependent ethnic convergence in colorectal cancer survival in Hawaii. BMC Cancer (2003) 0.88
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis (2005) 0.87
Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort. Br J Cancer (2014) 0.83
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs (2000) 0.82
Colorectal cancer treatment in older patients. Gastrointest Cancer Res (2007) 0.82
Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer (2014) 0.82
Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: impact of patient education before treatment initiation. J Gastrointest Oncol (2014) 0.81
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer. J Gastrointest Cancer (2013) 0.81
CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer. Oncotarget (2015) 0.80
The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. J Transl Med (2014) 0.80
cDNA array analysis for prediction of hepatic metastasis of colorectal carcinoma. Surg Today (2006) 0.80
Influence of socioeconomic status and hospital type on disparities of lymph node evaluation in colon cancer patients. Cancer (2011) 0.79
The establishment of a large collaborative trial programme in the adjuvant treatment of colon cancer. Br J Cancer (1998) 0.79
Adjuvant chemotherapy for colon carcinoma with positive lymph nodes: use and benefit in routine health care practice. Br J Cancer (2001) 0.79
Effects of Triterpenoid Glycosides from Fresh Ginseng Berry on SW480 Human Colorectal Cancer Cell Line. Cancer Res Treat (2011) 0.79
Adjuvant treatment of colorectal cancer. Gastrointest Cancer Res (2008) 0.79
Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study. World J Surg (2005) 0.78
Colorectal cancer treatment. BMJ Clin Evid (2010) 0.78
Adjuvant therapies for colorectal cancer. World J Gastroenterol (2007) 0.78
Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer (2004) 0.78
Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am (2010) 0.78
T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. World J Surg Oncol (2015) 0.78
Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer. Int J Colorectal Dis (2011) 0.78
The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients. Cancer Med (2016) 0.77
Biological predictors of survival in stage II colorectal cancer. Mol Clin Oncol (2013) 0.77
Colorectal cancer: from epidemiology to current treatment. Libyan J Med (2006) 0.77
Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer. J Korean Soc Coloproctol (2011) 0.77
Saudi Oncology Society clinical management guideline series. Colorectal cancer 2014. Saudi Med J (2014) 0.77
Sequential surgical resection of hepatic and pulmonary metastases from colorectal cancer. Langenbecks Arch Surg (2010) 0.77
Factors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer. Curr Oncol (2014) 0.77
Preoperative thrombocytosis predicts prognosis in stage II colorectal cancer patients. Ann Surg Treat Res (2016) 0.76
Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer. World J Surg (2013) 0.76
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer (2002) 0.75
Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer. Transl Oncol (2016) 0.75
Herbal Formulation C168 Attenuates Proliferation and Induces Apoptosis in HCT 116 Human Colorectal Carcinoma Cells: Role of Oxidative Stress and DNA Damage. Evid Based Complement Alternat Med (2016) 0.75
MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep (2017) 0.75
Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough? Springerplus (2016) 0.75
Oncologic Outcomes of Stage IIIA Colon Cancer for Different Chemotherapeutic Regimens. J Korean Soc Coloproctol (2012) 0.75
Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr Oncol (2016) 0.75
Stage III colon cancer at Baylor University Medical Center at Dallas and the Baylor Sammons Cancer Center: experience from 2000 to 2004. Proc (Bayl Univ Med Cent) (2006) 0.75
Update in internal medicine. Arch Med Res (2000) 0.75
Biotherapy in the Adjuvant Treatment of Colorectal Cancer. Gastroenterology Res (2011) 0.75
MRI and its importance in rectal cancer. Cancer Imaging (2000) 0.75
Desmoplasia influenced recurrence of disease and mortality in stage III colorectal cancer within five years after surgery and adjuvant therapy. Saudi J Gastroenterol (2017) 0.75
High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population. Int Sch Res Notices (2015) 0.75
Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer. PLoS One (2017) 0.75
Colon cancer: survival after curative surgery. Langenbecks Arch Surg (2004) 0.75
Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database. Langenbecks Arch Surg (2016) 0.75
Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients. Int J Clin Oncol (2012) 0.75
Final report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japan. Int J Clin Oncol (2017) 0.75
High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. J Cancer Res Clin Oncol (2016) 0.75
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med (2001) 18.77
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 9.70
A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med (1990) 7.92
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med (1998) 7.60
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med (2001) 7.59
Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med (1991) 7.21
Carcinoid tumors. N Engl J Med (1999) 6.44
Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst (1999) 5.92
Gastric carcinoma. N Engl J Med (1995) 5.77
Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol (2003) 5.71
Informed consent for genetic research on stored tissue samples. JAMA (1995) 5.54
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA (1993) 5.43
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA (1997) 4.79
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet (2000) 4.43
Genetic discrimination and health insurance: an urgent need for reform. Science (1995) 4.08
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol (1989) 4.03
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA (1993) 3.91
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst (1996) 3.53
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med (1994) 3.29
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst (2000) 3.27
Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med (1998) 2.95
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res (1998) 2.56
Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol (2001) 2.54
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol (1991) 2.46
Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med (1991) 2.37
Primary central nervous system lymphoma. Ann Intern Med (1993) 2.36
Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood (1991) 2.35
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Survival after postoperative combination treatment of rectal cancer. N Engl J Med (1986) 2.24
Carcinoma of the anal canal. N Engl J Med (2000) 2.22
Temperature and Excitability. J Physiol (1896) 2.21
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res (1998) 2.21
Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet (1992) 2.15
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol (1995) 2.02
Chemoprevention of colorectal cancer. N Engl J Med (2000) 1.98
Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol (1999) 1.95
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol (1991) 1.93
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst (1990) 1.92
Attitudes and practices of U.S. oncologists regarding euthanasia and physician-assisted suicide. Ann Intern Med (2000) 1.90
Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol (2001) 1.87
Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res (1989) 1.86
An effect of pactamycin on the initiation of protein synthesis in reticulocytes. Biochem Biophys Res Commun (1970) 1.79
Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med (2000) 1.79
Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA (1997) 1.78
Wound recurrence following conventional treatment of colorectal cancer. A rare but perhaps underestimated problem. Dis Colon Rectum (1996) 1.77
Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.67
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol (2002) 1.62
Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol (1996) 1.59
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst (1996) 1.58
A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03. Dis Colon Rectum (1997) 1.58
Designs for group sequential phase II clinical trials. Biometrics (1987) 1.57
Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry (1989) 1.57
A filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunocytochemical localisation of ubiquitin. Neurosci Lett (1988) 1.55
Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol (1989) 1.54
Natural history of hereditary cancer of the breast and colon. Cancer (1982) 1.53
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol (1989) 1.53
Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 1.52
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol (1993) 1.52
Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol (1990) 1.51
B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest (1984) 1.51
Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys (1996) 1.50
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol (2001) 1.50
Attitudes and practices among pediatric oncologists regarding end-of-life care: results of the 1998 American Society of Clinical Oncology survey. J Clin Oncol (2001) 1.48
Adenocarcinoma of the esophagus and esophago-gastric junction: the effects of single and combined modalities on the survival and patterns of failure following treatment. Int J Radiat Oncol Biol Phys (1990) 1.48
Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer. J Clin Oncol (2000) 1.42
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42